Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China [2] - The partnership includes exclusive rights for Changchun Jin Sai Pharmaceutical Co., Ltd. to market three products developed by ALK in mainland China [2] Company Summary - Changchun High-tech's subsidiary, Changchun Jin Sai Pharmaceutical, will work with ALK-Abelló A/S on AIT products targeting house dust mites (HDM) [2] - The collaboration aims to leverage ALK's expertise in immunotherapy to enhance product offerings in the Chinese market [2] Industry Summary - The partnership signifies a growing trend in the immunotherapy sector, particularly in addressing allergic conditions in China [2] - The exclusive rights to market ALK's products may strengthen Changchun High-tech's position in the competitive pharmaceutical landscape [2]

Group 1 - The core point of the article is that Changchun High-tech (SZ 000661) announced a collaboration with Danish company ALK-Abelló A/S for allergen-specific immunotherapy (AIT) products during its board meeting on September 17, 2025 [1] - For the first half of 2025, the revenue composition of Changchun High-tech was as follows: 92.83% from the pharmaceutical industry, 6.81% from real estate, and 0.36% from services [1] - As of the report date, the market capitalization of Changchun High-tech was 50.5 billion yuan [1]